$1.74
11.22%
Nasdaq, Oct 15, 03:59 pm EDT. Closed.
ISIN
US31447E1055
Symbol
FEMY

Femasys Inc Stock price

$1.74
-0.83 32.23% 1M
-6.85 79.78% 6M
-9.79 84.94% YTD
-9.28 84.24% 1Y
-26.47 93.85% 3Y
-138.27 98.76% 5Y
-238.27 99.28% 10Y
-238.27 99.28% 20Y
Nasdaq, Closing price Thu, Oct 15 2026
+0.18 11.22%

Is Femasys Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,109 stocks worldwide.

Key metrics

Basic
Market capitalization
$14.5m
Enterprise Value
$16.6m
Net debt
$2.1m
Cash
$1.4m
Shares outstanding
3.0m
Valuation
P/E
negative
P/S | estimate
6.3 | 6.0
EV/Sales | estimate
7.2 | 6.9
EV/FCF | ex SBC
negative | negative
P/B
3.6
Financial Health
Equity Ratio
28.3%
Return on Equity
-317.4%
ROCE
-209.1%
ROIC
-207.5%
Debt/Equity
0.9
Share-Based Compensation & Dilution
SBC | % of Revenue
$600.0k | 26.1%
SBC as % of FCF
-
SBC Growth 1Y
-25.9%
Share Count Growth 1Y
85.3%
Shareholder Yield
-85.3%
Financials
Revenue | estimate
$2.3m | $2.4m
EBITDA
$-17.2m
EBIT
$-17.6m
Net Income
$-11.8m
Free Cash Flow | ex SBC
$-18.2m | $-18.8m
Growth
Revenue | estimate
21.7% | 5.6%
EBITDA
8.4%
EBIT
8.3%
Net Income
44.0%
Free Cash Flow
10.9%
Margin
Gross
61.0%
EBITDA
-749.3%
EBIT
-763.9%
Net
-511.8%
Free Cash Flow | ex SBC
-791.0% | -817.3%
More
EPS
$-3.5
FCF per Share
$-6.0
Short interest
7.0%
Employees
53
Rev per Employee
$40.0k

Femasys Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Femasys Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Femasys Inc forecast:

Buy
89%
Hold
11%

Financial data from Femasys Inc

Jun '26
+/-
%
2.30 2.30
22% 22%
100%
- Direct Costs 0.90 0.90
36% 36%
39%
1.40 1.40
14% 14%
61%
- Selling and Administrative Expenses 12 12
9% 9%
530%
- Research and Development Expense 6.45 6.45
27% 27%
280%
-17 -17
8% 8%
-749%
- Depreciation and Amortization 0.34 0.34
3% 3%
15%
EBIT (Operating Income) EBIT -18 -18
8% 8%
-764%
Net Profit -12 -12
44% 44%
-512%

In millions USD.

Don't miss a Thing! We will send you all news about Femasys Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Femasys Inc Stock News

Neutral
GlobeNewsWire
●
one day ago
-- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval -- -- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval --
Neutral
GlobeNewsWire
●
8 days ago
ATLANTA, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it will exhibit at the American Society for Reproductive Medicine (ASRM) 2026 Scientific Co...
Neutral
GlobeNewsWire
●
about one month ago
-- Leading multi-site OB/GYN health practice to implement FemVue ® for fertility diagnostic evaluation and FemaSeed for first-line treatment across all four locations -- ATLANTA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of ...
More Femasys Inc News

Company Profile

Femasys, Inc. operates as a medical device company that focuses on women's healthcare. Its products include FemVue Saline-Air Device, which creates and delivers an alternating pattern of saline and air as a continuous stream, and enables physicians to assess their patients fallopian tubes, and FemChec Pressure Management Device, which limits the maximum applied pressure while performing hysterosalpingogram. The firm offers FemCerv, an endocervical curettage device to collect a non-contaminated tissue sample for cervical cancer screening. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

Head office United States
CEO Ms. Lee-Sepsick
Employees 53
Founded 2004
Website www.femasys.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today